Bragar Eagel & Squire Files Class Action Against Alexandria for 2025 Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Alexandria Real Estate Equities in the Central District of California on behalf of investors who purchased securities between January 27 and October 27, 2025, alleging the company made materially false and misleading statements during this period.
- Allegation Details: The complaint claims that Alexandria concealed significant adverse facts regarding the true state of its Long Island City property, particularly lacking a reasonable basis for its confidence in the leasing value related to its Megacampus™ strategy, misleading investors about the company's prospects.
- Investor Rights: Affected investors must apply by January 26, 2026, to be appointed as lead plaintiff in the lawsuit, with Bragar Eagel & Squire offering free consultations to assist investors in understanding their rights and options.
- Law Firm Overview: Bragar Eagel & Squire is a nationally recognized law firm specializing in representing individual and institutional investors in securities, derivative, and commercial litigation, with a broad nationwide practice.
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 64.78 USD with a low forecast of 30.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
9 Hold
1 Sell
Hold
Current: 57.260
Low
30.00
Averages
64.78
High
104.00
Current: 57.260
Low
30.00
Averages
64.78
High
104.00
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
